

DAFTAR PUSTAKA

- Ahmed, K. *et al* .2010. Extended spectrum β -lactamase mediated resistance in *Escherichia coli* in a tertiary care hospital in Kashmir, India. *Afr. J. Microbiol. Res*; 5(2): 2721-2728
- Anonim.2005. WHO Fact Sheet (<http://www.oneworldhealth.org>).
- Babini GS, Livermore DM .2000. Antimicrobial resistance amongst *Klebsiella* spp collected from intensive care units in Southern and Western Europe in 1997-1998. *J Antimicrob Chemother*; 45: 183-9.
- Baby Padmini S, *et. al*. 2004. Extended Spectrum Beta-Lactamase in urinary isolates of *Escherichia coli* and *Klebsiella sp* prevalence and susceptibility pattern in tertiary care hospital. *Indian J microbial*. 22(3) : 172-174.
- Basavaraj C Metri, *et. al*. 2011. The Prevalence of ESBL among enterobacteriaceae in a tertiary care Hospital of North Karnataka, India. *J clinical and diagnostic research*; 5(3): 470-475.
- Behroozi, A. *et al*. 2010. Frequency of extended spectrum beta-lactamase (ESBLs) producing *Escherichia coli* and *klebsiella pneumonia* isolated from urine in an Iranian 1000-bed tertiary care hospital. *Afr. J. Microbiol. Res*:5(2) : 881-884
- Bhattacharjee, A, Sen MR, Prakash P .2008. Increased Prevalence of ESBL on Neonatal Septicemic Cases at Tertiary Referral Hospital. In *J Med. Microbiol*;26(4) :356-60.
- Bronzwaer, SL., Cars, O., Buchhols, U., Molstad, S., Goettsch, W., *et al* .2002. A European Study on The Relationship between Antimicrobial Use and Antimicrobial Resistance, *Emerging Infectious Disease* () 8 : 278-282.
- Brooks, Geo F.; Butel, Janet S.; Morse, Stephen A. 2008. *Mikrobiologi Kedokteran Edisi 23*. Jakarta : EGC.
- Carol. A .2007. Firs Generation of Cephalosporine: summary of the first international symposium. *J Antimicrob Chemother. Clin Microbiol Rev*; 14:933-951.

- Chaudhary, U., Aggarwal R. 2004. Extended-Spectrum β -Lactamases (ESBL) – An Emerging Threat to Clinical Therapeutics. *Indian Journal of Medical Microbiology*. (<http://medind.nic/iau/t04/i2>, diakses tanggal 2 Oktober 2011).
- Cotton MF, Wasserman E, Pieper CH .2002. Invasive disease due to extended-spectrum β -lactamase producing *Klebsiella pneumoniae* in a neonatal unit: the possible role of cockroaches. *J Hosp Infect*; 44: 13-7.
- D’Azevedo PA, Goncalves ALS, Musskopf MI, Ramos CG, Dias CAG .2004. Laboratory tests in the detection of extended spectrum β -Lactamase production: National Committee for Clinical Laboratory Standards (NCCLS) screening test, the Etest, the double disk confirmatory list,. *Braz. J. Infect. Dis.*, 8(5): 372-377.
- Del Mar TM, Cartelle M, Pertega S, *et al* .2005. Hospital outbreak caused by a carbapenem-resistant strain of *Acinetobacter baumannii*: patient prognosis and risk-factors for colonisation and infection. *Clin Microbiol Infect*, **11**: 540–46.
- Dubreuil, J.D .2002. *Escherichia coli* STb enterotoxin, *Microbiology*,143; 1783–1795.
- Duttaroy B, Mehta S .2005. Extended spectrum β -lactamases (ESBL) in clinical isolates of *Klebsiella pneumoniae* and *Escherichia coli*. *Indian J. Pathol. Microbiol.*, 48(1): 45-48.
- Eslava, C. F. Navarro-García, J.R. Czeuczulin, I.R. Henderson, A. Cravioto, J.P. Nataro, Pet. .2009. an autotransporter enterotoxin from enteroaggregative *Escherichia coli*, *Infect. Immun.* 66 3155–3163.
- Farmer III, J. J., Boatwright, K.D., Micheal Janda, J.2007. Enterobacteriaceae: Introduction and Identification, p. 649-669. In P.R. Murray, Baron, E. J., Jorgensen, J.H., Pfaller, M.A., Tenover, R. H. (ed.), *Manual of Clinical Microbiology*, 9th ed, vol. 1. ASM Press, Washington, D.C.
- Hardjoeno. 2007. *Kumpulan Penyakit Infeksi dan Tes Kultur Sensitifitas Kuman Serta Upaya Pengendaliannya*. Cahya Dinan Rucitra. Makassar. Hal 158-165.
- Iroha, I.R., et al.2009. Extended Spectrum beta-lactamase (ESBL) in *E. coli* isolated from a tertiary hospital in Enugu State, Nigeria. *Pak. J. Med. Sci.*, 25: 279-288.
- Jabeen K, Zafar A, Hasan R .2005. Frequency and sensitivity pattern of extended spectrum β -Lactamase producing isolates in a tertiary care hospital laboratory of Pakistan. *J. Pak. Med. Assoc.*, 55(10): 436-439.
- Jain A, Roy I, Gupta M K, Kumar M, Agarwal SK .2003. Prevalence of Extended Spectrum β -Lactamases producing gram negative bacterial septicaemic neonates in a tertiary care hospital. *J. Med. Microbiol.*, 52: 421-425.

- Jawetz, E, Melnick, J, Aldenberg E. 2005. *Mikrobiologi Kedokteran*. EGC, Jakarta. hlm 786.
- Karch, H .2001. The role of virulence factors in enterohemorrhagic *Escherichia coli* (EHEC) associated hemolytic uremic syndrome, *Semin. Thromb. Hemost.* 27 ;207–214.
- Karowsky J A. *et. al.* 2010. Multidrug resistant urinary tract isolates of *Escherichia coli* : prevalence and patient demographics in the United states in 2009. *Antimicrob Agents Chemother* 2009; 45(5) : 1402-06.
- Katzung, Bertram G. 2010. *Farmakologi Dasar dan Klinik Edisi 10*. EGC, Jakarta.hlm 747.
- Kuehn, M.J. *et al.* .2010. Enterotoxigenic *Escherichia coli* secretes active heat-labile enterotoxin *via* outer membrane vesicles, *J. Biol. Chem.* 275. 12489–12496.
- Livermore DM. 2005. -lactamases in laboratory and clinical resistance. *Clin Microbiol Rev*; 8: 557-84.
- Maliku,Palupi. 2010. Pola Resistensi Isolat Bakteri Pada Luka Post Operasi di Bagian Rawat Inap Bedah RSUD Dr. H. Abdul Moeloek Bandar Lampung. (Skripsi). Universitas Lampung. 66 hlm.
- Mathur P. *et. al.* 2002. Prevalence of ESBL producing gram negative bacteria in a tertiary care hospital. *Indian J. Med. Res* ; 115: 153-157.
- Mycek, Mary J., Richard A Harvey., Pamela C Champe. 2001. *Farmakologi Ulasan Bergambar Edisi 2*. Widya Medika, Jakarta. hlm. 475.
- Naber KG, Carson C. 2004. Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections.; 64 (12): 1359-73.
- Nathisuwan S., Burgess D.S., Lewis II J.S. 2005. ESBLs : Epidemiology, Detection and Treatment. *Pharmacotherapy.* 21(8): 921-928.
- National Committee for Clinical Laboratory Standards. 2005. Performance standards for antimicrobial susceptibility testing; 15th informational supplement (M100-S15). *National Committee for Clinical Laboratory Standards*, Wayne, Pa.
- Nelwan RHH. 2002. Pemakaian antimikroba secara rasional di klinik. Dalam: Noer S, editor. *Buku Ajar Ilmu Penyakit Dalam*. Jakarta : Balai Penerbit FKUI,: 537-540
- Olowe, O.A., Aboderin, B.W .2010. Detection of Extended Spectrum –Lactamase producing strains of (*Escherichia coli*) and (*Klebsiella SP*) in a Tertiary Health Centre in Ogun State.*Int j of trop Med.*, 5(3) : 62-64.

- Pajariu, Agno .2010. Infeksi oleh bakteri penghasil ESBL di RSUP Dr. Kariadi Semarang: Faktor risiko terkait penggunaan antibiotic. Semarang: *Media Medika Indonesia*. Fakultas Kedokteran Universitas Diponegoro. 260 – 67.
- Parsot C.2005. *Shigella* spp. and enteroinvasive *E. coli* pathogenicity factors, *FEMS Microbiol. Lett.* 252 8–11.
- Paterson, David L., Bonomo, Robert A. 2010. Extended-Spectrum β -Lactamases : *a Clinical Update. Clinical Microbiology Review vol 18.* pp:657-686 (<http://cmr.asm.org/cgi/content/full/18/4/657>, diakses tanggal 4 Oktober 2011).
- Pavankumar, A.R. 2008. The Need and New Tools for Surveillance of *Escherichia coli* Pathogens, *Biotechnol.* 46 (2) 125–145.
- Prabaningrum,N.danSeptiana V. 2008. Cefotaxime. ([http://yosefw.wordpress.com/2008/03/Diakses tanggal 16 Oktober 2011](http://yosefw.wordpress.com/2008/03/Diakses%20tanggal%2016%20Oktober%202011)).
- Prescott, L.M., Harley, J.P Klein D.A. 2008. *Microbiology*, William C. Brown Publishers, Dubuque, IA, USA pp. 415–476.
- Rice L. 2005. Evolution and clinical importance of extended-spectrum β -lactamases. *Chest.*;119(2):391-6.
- Rupp .M. E. and Paul D. F. 2003. Extended Spectrum β -Lactamase (ESBL) Producing Enterobacteriaceae Considerations for Diagnosis, Prevention and Drug Treatment. Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA : 354-362
- Saepudin, Pajariu .2007. Perbedaan Penggunaan Antibiotika pada pengobatan pasien infeksi saluran kemih yang menjalani rawat inap di salah satu RSUD di Yogyakarta: *Media Medika Indonesia*. Fakultas Kedokteran Universitas Diponegoro. 260 – 67.
- Sharma S, *et. al.* 2007. Virulence factors and Drug resistance in *Escherichia coli* isolated from extra intestinal infections. *Indian J Med Microbiol*; 25 (4) : 369-373.
- Smyth EG, O'Connell N .2004. Complicated urinary tract infection. *Drugs & Therapy Perspectives*; 11(1): 63-6.
- Tsang DNC. Que TL, Ho M, Yuen K Y .2007. Comparison of Screening Methods for detection of ESBL and their prevalence among *E. coli* and *Klebsiella sp* in Hongkong. *APMIS.*;108;23.40.
- Tumbarello M .2010. Bloodstream Infections Caused by Extended-Spectrum- β -Lactamase-Producing *Klebsiella pneumoniae*: Risk Factors, Molecular Epidemiology, and Clinical Outcome; (<http://aac.asm.org/cgi/reprint/50/2/498>. diakses tanggal 28 November 2011).

- Urba'nek, K., M. Kolar., Y. Lovec'kova., J. Strojil., L. Santava. 2007. Influence of third-generation cephalosporin utilization on the occurrence of ESBL-positive *Klebsiella pneumoniae* strains. *Journal of Clinical Pharmacy and Therapeutics*. 32: 403–408.
- Whittam, T.S. *et. al.*2011. Pathogenesis and evolution of virulence in enteropathogenic and enterohemorrhagic *Escherichia coli*, *J. Clin. Invest.*107;539–548.
- Wiley, J., Sherwood, L., Woolverton, C. (2008). *Prescott, Harley, & Klein's Microbiology, 7 ed.* McGraw-Hill, New York, New York.
- Winarto. 2009. Prevalensi Kuman ESBL (*Extended Spectrum Beta Lactamase*) dari Material Darah di RSUP Dr. Kariadi Tahun 2004-2005. *Media Medika Indonesia*, Vol . 43.No. 5: 260-268.